NCT01990443View on ClinicalTrials.gov

Absolute Bioavailability of Reslizumab in Healthy Subjects

PHASE1CompletedINTERVENTIONAL
Enrollment

75

Participants

Timeline

Start Date

June 30, 2013

Primary Completion Date

December 31, 2013

Study Completion Date

March 31, 2014

Conditions
Absolute Bioavailability
Interventions
DRUG

Reslizumab IV

Reslizumab 220-mg intravenous (IV)

DRUG

Reslizumab SC

Reslizumab 220 mg administered subcutaneous (SC)

Trial Locations (1)

Unknown

Teva Investigational Site 10567, Anaheim

All Listed Sponsors
lead

Teva Branded Pharmaceutical Products R&D, Inc.

INDUSTRY

NCT01990443 - Absolute Bioavailability of Reslizumab in Healthy Subjects | Biotech Hunter | Biotech Hunter